KLK3 and posterior cortical atrophy: An analysis of the randomized phase III RTOG 94-08 trial of patients with clinically localized PCa (T1b–2b; prostate-specific antigen [PSA] < 20 ng/mL) demonstrated that 4 months of ADT (with an LHRH agonist and an antiandrogen) plus radiotherapy improved overall survival (OS) and disease-specific survival (DSS), with no elevated 10-year risk of CV mortality (unadjusted HR 1.07; 95% CI 0.81–1.42; P = 0.62), compared with radiotherapy alone (31).